IpiNovyx Bio

IpiNovyx Bio is a drug development and platform technology company focused on novel therapies for autoimmune and inflammatory diseases through selective inhibition of the immunoproteasome. IpiNovyx Bio's platform technology enables highly selective, reversible, and non-toxic inhibition of various immune cell types. These innovative small molecule inhibitors are designed to selectively target the immunoproteasome and modulate specific immune cell types associated with autoimmune and inflammatory diseases. Importantly, preclinical studies indicate that, due to their ability to inhibit immune responses without killing immune cells, these compounds may exhibit a favorable toxicity profile compared to immunosuppressive therapies. Additionally, the inhibitory activity of the company’s lead candidates is reversible, further reducing the likelihood of toxicity.